BioCorRx to Present at the 31st Annual ROTH Conference on March 17-19, 2019
ANAHEIM, CA, March 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that the Company has been invited to present at the 31st Annual ROTH Conference being held at The Ritz Carlton, Laguna Niguel in Orange County, California, on March 17-19, 2019.
The conference will feature presentations from public and private companies across a variety of industries. Last year, the ROTH conference hosted approximately 550 participating companies and more than 4,700 attendees – including institutional investors, analysts, family offices and high net-worth investors.
Brady Granier, President and Chief Executive Officer, and Lourdes Felix, Chief Financial Officer and Chief Operating Officer, are scheduled to present in one-on-one meetings with institutional analysts and investors held throughout the day on Monday, March 18.
Additionally, Granier is scheduled to participate on a panel titled “Battling Addiction” on Monday, March 18 at 10:00 a.m. PST.
ROTH hosted a pre-recorded webcast of the Company’s presentation, which is available at http://wsw.com/webcast/roth33/BICX/ and in the investor section of the Company’s website. To schedule a one-on-one meeting with BioCorRx please contact your ROTH representative.
About Roth Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids, and can prevent opioid overdose following relapse. The second component of the program developed by BioCorRx Inc. is a Cognitive Behavioral Therapy (CBT) program tailored specifically for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc. investors@BioCorRx.com (714)462-4880 Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 firstname.lastname@example.org Media Contact: CMW Media (858) 264-6600 email@example.com
Released March 14, 2019